Penta Valent (PEVE) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Penta Valent stock IDR 658, price IDR 328, upside +100.6%, quality 47 out of 100. Rating: strongly undervalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 3, 2026.
How to read this chart
46‑month range 139.00 IDR – 635.00 IDR · fair‑value band 493.53 IDR – 849.08 IDR · the 328.00 IDR price screens below the 658.05 IDR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 3, 2026.
Follow Penta Valent in your weekly email
Every Wednesday you see whether Penta Valent is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
PT. Penta Valent Tbk engages in the distributions of pharmaceutical products, medical equipment, and consumer products in Indonesia. The company was founded in 1968 and is headquartered in Kebon Jeruk, Indonesia.
Stock analysis
Penta Valent (PEVE) currently trades at 328.00 IDR, while our model-based Fair Value estimate is 658.05 IDR, implying the stock looks roughly 50% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 807.14 IDR per share, and 11 of the 13 models we run sit above the 328.00 IDR price.
Bear case: the Asset-Based group reads lowest at 171.47 IDR, and 2 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: 493.53 IDR (bear) to 849.08 IDR (bull), the price of 328.00 IDR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Penta Valent reported revenue of 3.5T IDR in FY2025 versus 2.1T IDR in FY2022, a compound +18.2%/yr. Reported net income was 55.3B IDR in FY2025, compounding +32.9%/yr from FY2022.
Key figures
Market cap 579B IDR (≈ $32.2M) Micro · P/S ratio 0.16 · Net margin 1.6% · Return on equity 16.3% · Return on assets (EBIT) 5.5% (4-year average) · Operating margin 2.6% · Revenue (TTM) 3.7T IDR · Revenue growth (YoY) +14.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 40 out of 100 (low confidence).
What moves the price
The share trades about 48% below its 52-week high and 17% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 19% fair-value upside, at 101%, PEVE screens cheaper than that median.
Fair Value models
Bear493.53 IDRFair Value 658.05 IDRBull849.08 IDR
Price 328.00 IDR · Upside +100.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+17.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.2%
’22
’23
’24
’25
What shareholders gained per year (last 3 years), in IDR (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip. Measured in IDR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+32.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+32.8%
Dividend (yield on the price)0.0%
Profit margin 2022 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.2% → 3%
2025 sits 53% above its own trend. The rate follows the median trend of the last 3 years, not that single year.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceutical Retailers · 50 stocks
Beats the industry median on 7/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score47 · Bottom 25%
Fair Value upside+99.4% · Top 25%
Profitability
Return on equity (12 months)16.3% · Top 25%
Return on assets4.0% · Above median
Net margin (12 months)1.6% · Below median
Operating margin (12 months)2.6% · Below median
Growth and dividend
Revenue growth (quarter YoY)14.1% · Top 25%
Valuation Multiplesvs Pharmaceutical Retailers median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Penta Valent Fair Value". https://www.fairvalue-calculator.com/stock/PEVE
Frequently asked questions
Is Penta Valent (PEVE) overvalued or undervalued?
As of Nov 3, 2026, our model estimates a fair value of 658.05 IDR versus a price of 328.00 IDR, about +101% upside (undervalued).
What is the fair value of PEVE?
Our model-based fair value for Penta Valent is 658.05 IDR (as of Nov 3, 2026), built from audited fundamentals. The current price: 328.00 IDR.
What is the quality score of PEVE?
Penta Valent has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Penta Valent (PEVE)?
Our model-based price target is the fair value of 658.05 IDR (as of Nov 3, 2026) from 13 valuation models. Cautious scenario 493.53 IDR, optimistic scenario 849.08 IDR. It is a calculation from audited fundamentals, not an analyst target.
What is the Penta Valent stock forecast for 2026?
Our models put fair value at 658.05 IDR, about +101% upside versus a price of 328.00 IDR (undervalued). Cautious scenario 493.53 IDR, optimistic scenario 849.08 IDR. The calculation is refreshed regularly with new filings.
What is the revenue of Penta Valent (PEVE)?
Penta Valent reported trailing-twelve-month revenue of about 3.7T IDR (latest available figure, as of Nov 3, 2026).
What is the intrinsic value of Penta Valent (PEVE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Penta Valent it is 658.05 IDR per share (as of Nov 3, 2026), against a price of 328.00 IDR. It is the blended result of 13 valuation models in 5 families (Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Penta Valent stock overvalued or undervalued in 2026?
As of Nov 3, 2026, PEVE trades below its calculated fair value: price 328.00 IDR, fair value 658.05 IDR, a gap of about +101% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PEVE?
No. The price is what the market pays today (328.00 IDR); the fair value is what the company's own numbers justify (658.05 IDR). For Penta Valent the two are 330.05 IDR per share apart. That gap is exactly why we show both numbers side by side.
How much is Penta Valent worth?
The market values Penta Valent at about 579B IDR (market capitalisation, as of Nov 3, 2026). Per share that is 328.00 IDR; our models calculate a fair value of 658.05 IDR per share.
What do the bullish and bearish scenarios say about PEVE?
Our models span a range for Penta Valent: cautious scenario 493.53 IDR, base 658.05 IDR, optimistic 849.08 IDR per share (as of Nov 3, 2026, price 328.00 IDR). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Penta Valent (PEVE)?
Balance-sheet figures for Penta Valent (as of Nov 3, 2026): return on equity 16.3%. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is PEVE from its 52-week high?
Penta Valent trades at 328.00 IDR, about 48% below its 52-week high of 635.00 IDR and 17% above the low of 280.00 IDR (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of 658.05 IDR is for.
Which stocks are comparable to Penta Valent?
From the same area (Healthcare) we also value JD Health International Inc, Yifeng Pharmacy Chain Co, DaShenLin Pharmaceutical Group, LBX Pharmacy Chain Joint Stock Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Penta Valent stock attractive at the current price?
The data as of Nov 3, 2026: price 328.00 IDR, calculated fair value 658.05 IDR (+101%), Quality Score 47/100, from 13 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PEVE calculated?
We run Penta Valent through 13 models from 5 families: Earnings-Based, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 658.05 IDR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Penta Valent currently trades 50% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Penta Valent (PEVE)?
The closing price on Nov 9, 2026 was 328.00 IDR. Our model-based fair value is 658.05 IDR, about +101% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Penta Valent right now?
The large discount to fair value meets weak quality (47/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case (493.53 IDR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Penta Valent
How large is the market capitalisation of Penta Valent (PEVE)?
The market capitalisation of Penta Valent is 579B IDR (≈ $32.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Penta Valent (PEVE)?
The price-to-sales ratio of Penta Valent is 0.16 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Penta Valent (PEVE)?
The net margin of Penta Valent is 1.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Penta Valent (PEVE)?
The return on equity (ROE) of Penta Valent is 16.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Penta Valent (PEVE)?
On an EBIT basis the return on assets of Penta Valent is 5.5% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Penta Valent (PEVE)?
The operating margin of Penta Valent is 2.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Penta Valent (PEVE)?
Revenue at Penta Valent is growing +14.1% versus a year earlier (3y avg +18.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Penta Valent (PEVE)?
Earnings per share at Penta Valent are growing +12.2% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Penta Valent in the live analysis
One click puts Penta Valent on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 3, 2026